Alkermes plc
Organization details
- Legal name
- Alkermes plc
- Former names
- Antler Science Two PLC
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- Dublin 4
- Headquarters country
- Ireland
- Fiscal year end
- December
- Ticker symbol
- ALKS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001520262
- EIN
- 98-1007018
Board of directors
-
Anne Clem Whitaker · DirectorSince 2026
-
Blair Curtis Jackson · Director · President & CEO, Alkermes plcSince 2026
-
Brian P. Mckeon · DirectorSince 2023
-
Cato T. Laurencin · DirectorSince 2023
-
Christopher I. Wright · DirectorSince 2023
-
David Angelo Daglio Jr. · DirectorSince 2023
-
Emily Peterson Alva · DirectorSince 2023
-
Frank Anders Wilson · DirectorSince 2023
-
Nancy Lurker · DirectorSince 2024
-
Nancy Lynn Snyderman M.D. · DirectorSince 2023
-
Nancy Wysenski · DirectorSince 2023
-
Richard F. Pops · Director · Director and CEO, Alkermes plcSince 2023
-
Richard Gaynor · DirectorSince 2023
-
Shane Cooke · DirectorSince 2023
Chief executives
Director election results
Annual meeting of May 20, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
95.3%
-
96.1%
-
96.3%
-
96.7%
-
98.4%
-
98.5%
-
98.6%
-
98.7%
-
99.2%
Board connections
10 of this board's directors also sit on 13 other boards. 10 are in the same sector.
-
Amneal Pharmaceuticals Inc. Same sectorvia Emily Peterson Alva
- via Frank Anders Wilson
-
Collegium Pharmaceutical Inc. Same sectorvia Nancy Lurker
-
Cytokinetics Incorporated Same sectorvia Nancy Wysenski
-
DENTSPLY SIRONA Inc. Same sectorvia Brian P. Mckeon
- via Nancy Lurker
-
ICON plc Same sectorvia Anne Clem Whitaker
-
MiMedx Group Inc Same sectorvia Cato T. Laurencin
-
Neurocrine Biosciences Inc. Same sectorvia Richard F. Pops
- via Frank Anders Wilson
-
OraSure Technologies Inc. Same sectorvia Anne Clem Whitaker
-
Prothena Corporation plc Same sectorvia Shane Cooke
-
Zai Lab Limited Same sectorvia Richard Gaynor
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $10,099,559
- 33 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 3, 2026 | Gaffin David Joseph Officer (EVP, CLO, Alkermes, Inc.) | Open-market sale | −2,035 | $46.17 | $93,956 |
| Oct 8, 2026 | Joshua Reed Officer (SVP, Chief Financial Officer) | Option exercise | +9,164 | — | — |
| Oct 8, 2026 | Joshua Reed Officer (SVP, Chief Financial Officer) | Shares withheld for tax | −4,069 | $40.11 | $163,208 |
| Oct 2, 2026 | Gaffin David Joseph Officer (EVP, CLO, Alkermes, Inc.) | Open-market sale | −2,034 | $41.03 | $83,455 |
| Sep 3, 2026 | Gaffin David Joseph Officer (EVP, CLO, Alkermes, Inc.) | Open-market sale | −2,034 | $48.01 | $97,652 |
| Sep 1, 2026 | Hopkinson Craig C. Officer (EVP R&D, Chief Medical Officer) | Option exercise | +5,000 | $24.59 | $122,950 |
| Sep 1, 2026 | Hopkinson Craig C. Officer (EVP R&D, Chief Medical Officer) | Open-market sale | −9,000 | $46.99 | $422,910 |
| Aug 17, 2026 | Nichols Christian Todd Officer (SVP, Chief Commercial Officer) | Open-market sale | −6,912 | $49.19 | $340,001 |
| Aug 17, 2026 | Nichols Christian Todd Officer (SVP, Chief Commercial Officer) | Open-market sale | −664 | $49.65 | $32,968 |
| Aug 3, 2026 | Gaffin David Joseph Officer (EVP, CLO, Alkermes, Inc.) | Open-market sale | −2,034 | $48.58 | $98,812 |
| Aug 3, 2026 | Hopkinson Craig C. Officer (EVP R&D, Chief Medical Officer) | Option exercise | +104 | $19.34 | $2,011 |
| Aug 3, 2026 | Nancy Lynn Snyderman M.D. Director | Option exercise | +27,948 | $46.72 | $1,305,731 |
| Aug 3, 2026 | Hopkinson Craig C. Officer (EVP R&D, Chief Medical Officer) | Option exercise | +4,896 | $24.59 | $120,393 |
| Aug 3, 2026 | Nancy Lynn Snyderman M.D. Director | Option exercise | +16,524 | $46.72 | $772,001 |
| Aug 3, 2026 | Hopkinson Craig C. Officer (EVP R&D, Chief Medical Officer) | Open-market sale | −9,000 | $48.58 | $437,220 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Alkermes plc
Who is the CEO of Alkermes plc?
Richard F. Pops is Alkermes plc's Director and CEO, Alkermes plc.
How many directors are on Alkermes plc's board?
Alkermes plc's board has 14 directors: Anne Clem Whitaker, Blair Curtis Jackson, Brian P. Mckeon, Cato T. Laurencin, Christopher I. Wright, David Angelo Daglio Jr., Emily Peterson Alva, Frank Anders Wilson, Nancy Lurker, Nancy Lynn Snyderman M.D. and 4 others.
Are Alkermes plc insiders buying or selling shares?
Over the last 12 months, Alkermes plc insiders made no open-market purchases and sold $10.1 million of shares in 33 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="alkermes-plc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.